With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the ... Show More
Jun 25
Ep. 312 Managing Intravesical Therapy Toxicities in Bladder Cancer with Dr. Meredith Donahue and Mary Dunn, NP
How can clinics minimize toxicity and maximize outcomes in intravesical bladder cancer treatment? In this episode of BackTable Urology, host Dr. Vignesh Packiam talks with nurse practitioners Mary Dunn (UNC) and Meredith Donahue (Vanderbilt) about how advanced practice providers ... Show More
30m 37s
Jun 2025
Ep. 553 Dosimetry University Part II: Understanding Partition and Voxel-Based Approaches with Dr. Tyler Sandow and Dr. Nima Kokabi
BSA, MIRD, or voxel-based dosimetry? Join us for part 2 of Dosimetry University where interventional oncologists Dr. Tyler Sandow, Dr. Nima Kokabi, and Dr. Kavi Krishnasamy explore and debate the critical nuances of a successful Y90 procedure, covering dosing methods, lung shunt ... Show More
1h 1m
Feb 2024
Key Advances in Prostate, Kidney, and Bladder Cancers at GU24
<p>Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influen ... Show More
30m 6s
Jan 2024
What's New in Prostate Cancer, RCC, and mUC at GU24
<p>Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ... Show More
25m 10s
Dec 2023
UROONCO RCC take home message for 2023
<p>In this podcast, UROONCO RCC board members, chief editor Dr. Carmen Mir (ES), and associate editors Dr. Riccardo Bertolo (IT) and Dr. Teele Kuusk (GB), discuss the progress made in the field of kidney cancer during 2023, and what is anticipated for 2024.<br/><br/>Some topics d ... Show More
18m 27s
Oct 2022
Dr Thomas Seisen talks about treatment options for metastatic UTUC
<p>During this episode, Dr. Thomas Seisen (FR), an associate member on the EAU Guidelines Panel for Non-Muscle Invasive Bladder Cancer, answers questions about metastatic upper urothelial cancer (UTUC) treatment options in the 2022 guidelines:</p><ul><li>What are the systemic tr ... Show More
17m 11s
